Background:Acute respiratory distress syndrome (ARDS) due to coronavirus 2019 (COVID-19) can result in severe disease requiring mechanical ventilatory support.A subset of these patients, however, demonstrate refractory hypoxemia/hypercarbia requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO) as adjunctive therapy.The primary goal of V-V ECMO is a "bridge" to recovery of native lung function; however, patients may progress to irreversible pulmonary damage requiring lung transplantation. Material/Methods:We conducted a retrospective review of patients with refractory COVID-19 ARDS/pulmonary fibrosis that required a V-V ECMO bridge to lung transplantation at our institution from May 2021 to December 2022.Data for analysis included patient demographics, pre/post-transplantation course, and 1-year outcomes. Results:Nine patients (6 male, 3 female) with an average age of 44.6±12.1 years required V-V ECMO support for COVID-19 and subsequently underwent lung transplantation.The median number of ECMO days was 57 (IQR 53-78).At listing, these patients had a median lung allocation score (LAS) of 91.86 ).The median hospital length-of-stay was 89 days (IQR 54-144) with the longest hospital stay at 255 days.All patients were discharged home and survived to 1-year post-transplant. Conclusions:Our case series shows that patients with COVID-19 ARDS/pulmonary fibrosis had no meaningful difference in overall survival compared to our institution's overall 1-year lung transplant survival rate.Our results suggest that with careful selection and care, long-term lung transplantation outcomes can be equivalent for those requiring a bridge to transplantation with V-V ECMO support despite the severity of illness in the peri-transplant period.

Mazen F. Odish

Travis Pollema

Christine M. Lin

Robert L. Owens

Cassia Yi

Shannon LeBlanc

Chelsea Roche

Catherine Gaissert

Gordon Yung

Aarya Kafi

Eugene M. Golts

Kamyar Afshar

Annals of Transplantation

ANNALS OF TRANSPLANTATION 是快速发展的期刊之一，向所有科学家和移植医学及相关研究领域开放。该杂志每季度出版一次，广泛报道移植领域最重要的进展。使用电子在线提交和同行评审跟踪系统，《移植年鉴》致力于快速评审和出版。第一次做出决定的平均时间约为 3-4 周。接受稿件的发表时间不断缩短，编辑团队致力于实现从接受到发表 3 个月的目标。来自世界各地的专家研究人员和临床医生在每个相关领域贡献了原创文章、评论论文、病例报告和特别报告专业，为讨论该领域令人兴奋的发展和争议提供了很多论据。

The Annals of Transplantation is a rapidly evolving journal open to all scientists and researchers in the field of transplantation medicine and related studies. Published quarterly, the journal extensively reports on significant advancements in the field of transplantation. Utilizing an electronic online submission and peer review tracking system, the journal is committed to rapid review and publication. The average time to make the first decision is approximately 3-4 weeks, and the time from acceptance to publication is continuously decreasing, with the editorial team aiming to achieve a target of 3 months. Experts and clinicians from around the world contribute original articles, review papers, case reports, and special reports in various relevant fields, providing ample arguments for discussions on exciting developments and controversies in the field.

《Annals of Transplantation》是一个快速发展的期刊，向所有科学家和移植医学及相关研究领域的研究者开放。该杂志每季度出版一次，广泛报道移植领域的重要进展。期刊采用电子在线提交和同行评审跟踪系统，致力于快速评审和出版。第一次做出决定的平均时间约为3-4周，接受稿件的发表时间不断缩短，编辑团队的目标是实现从接受到发表的时间控制在3个月内。来自世界各地的专家研究人员和临床医生在各个相关领域贡献原创文章、评论论文、病例报告和特别报告，为讨论该领域的最新发展和争议提供了丰富的论据。

Category	Quartile
医学	4
医学, 外科	4
医学, 移植	4

Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-Up

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info